Catrin Treharne has been appointed as a principal at LCP.
She brings over 11 years experience in health economics and joins LCP from Mtech Access, a company specialising in pharmaceutical and medtech market access.
There she co-led the health economics team, and her previous experience also includes roles at Parexel and Abacus International.
Treharne has expertise in economic evaluation across a wide number of disease areas, with recent work covering oncology, gastroenterology, nephrology, and mental health.
Her experience spans the product lifecycle, from early economic models, to global models suited for health technology assessment, as well as models developed for use with local payers.
And her work has been published across a range of disease areas, including chronic obstructive pulmonary disease (COPD), multiple sclerosis, and end-stage renal disease.
This senior appointment will further bolster the expertise of the growing health analytics department at LCP, which has grown to more than 30 people since it was formed in August 2020.
Maisie Borrows also joined earlier this month as a strategic growth lead, bringing experience from the pharmaceutical, policy, and consulting space.
She previously worked for Novartis Innovative Medicines in the global and country affiliate teams, building expertise in the strategy and market access space.
LCP’s health analytics team is led by Dr Jonathan Pearson-Stuttard, who is also chair of the Royal Society for Public Health.
He said: “Our health and the challenges facing health systems are changing.
“The greatest threats are no longer single diseases, but the increasingly-complex health demands from ageing populations with increasing multimorbidity.
“Catrin’s expertise and knowledge of health economic modelling will be invaluable in helping our clients ensure provision and access are targeted proportionately to those who need it most and the greatest returns to the wider health system.”
Treharne added: “LCP’s health team is quickly becoming recognised and respected for its ability to understand the changes happening in the sector.
“I am looking forward to bringing my passion and expertise to the team and expanding its horizons with the pharmaceutical industry.”
